Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Invivyd (Nasdaq: IVVD) granted inducement stock options to four newly hired non-executive employees on March 1, 2026, totaling 192,000 shares under the 2026 Inducement Plan.

The options carry a $1.69 exercise price (closing price Feb 27, 2026), vest over four years (25% after one year, then monthly), have a 10-year term, and were granted under Nasdaq Listing Rule 5635(c)(4).

News Market Reaction – IVVD

-5.81%

2 alerts

-5.81% News Effect

-$28M Valuation Impact

$451.18M Market Cap

0.0x Rel. Volume

On the day this news was published, IVVD declined 5.81%, reflecting a notable negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $28M from the company's valuation, bringing the market cap to $451.18M at that time.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -5.8% in the session following this news. A negative reaction despite the largely ro...

Analysis

The stock moved -5.8% in the session following this news. A negative reaction despite the largely routine nature of inducement grants would fit a pattern where secondary factors influence trading. The award of 192,000 options at $1.69 under a 10-year term may highlight compensation and overhang concerns alongside an existing S-3 shelf. Past trading around news showed at least one sharp decline even on positive trial planning, suggesting sentiment can decouple from fundamentals.

Key Figures

Inducement option grants: 192,000 shares New hires: 4 employees Option exercise price: $1.69 per share +5 more

8 metrics

Inducement option grants 192,000 shares Aggregate options to four new non-executive employees

New hires 4 employees Non-executive employees receiving inducement options

Option exercise price $1.69 per share Set at Feb 27, 2026 closing price

Vesting period 4 years Options vest over four years, service-based

Initial vesting cliff 25% after 1 year First vesting on first anniversary of start date

Option term 10 years Maximum life of each inducement option

Grant date March 1, 2026 Date options were granted under inducement plan

Reference price date February 27, 2026 Last trading day before grant used to set exercise price

Historical Context

5 past events · Latest: Feb 24 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 24	Clinical publication	Positive	+5.0%	Peer-reviewed correlate-of-protection model for COVID-19 mAb across variants.
Feb 03	Phase 3 planning	Positive	+8.1%	FDA alignment on LIBERTY Phase 3 trial comparing VYD2311 to mRNA vaccines.
Jan 22	Marketing partnership	Neutral	+0.0%	Education partnership with Lindsey Vonn to raise antibody awareness.
Jan 20	Trial initiative	Positive	-8.6%	Planned Phase 2 study of VYD2311 for long COVID and vaccine-injured patients.
Jan 08	Prelim earnings	Positive	+4.6%	Preliminary Q4 2025 PEMGARDA revenue growth and pipeline progress highlights.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news has focused on COVID-19 antibody development, late-stage trials, and a commercial launch ramp. Positive clinical and revenue updates often saw aligned price gains, while one long COVID trial-planning release coincided with a notable selloff, showing occasional divergence even on constructive pipeline news.

Recent Company History

Over the last few months, Invivyd reported several COVID-19 antibody milestones and commercial updates. On Jan 8, preliminary Q4 2025 results highlighted $17.2M PEMGARDA revenue and strong cash, followed by multiple Phase 2/3 plans for VYD2311 in prevention and long COVID. A Feb 3 FDA alignment and a Feb 24 publication on variant-agnostic protection both saw positive price reactions. Today’s inducement grants represent routine equity compensation rather than a development milestone.

Key Terms

nasdaq listing rule 5635(c)(4)

1 terms

nasdaq listing rule 5635(c)(4) regulatory

"The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on March 1, 2026, Invivyd granted four newly hired non-executive employees options to purchase an aggregate of 192,000 shares of its common stock, each as a material inducement for each employee’s entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan.

The options have a per share exercise price of $1.69, representing the closing price of Invivyd’s common stock on February 27, 2026, the last trading date prior to the date of grant. Each option vests over four years, with 25% of the shares subject to such option vesting on the first anniversary of the employee’s start date and the remaining shares vesting in equal monthly installments thereafter, in each case, subject to the employee’s continuous service with Invivyd. The options have a 10-year term and are subject to the terms of the Invivyd, Inc. 2026 Inducement Plan.

About Invivyd

Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more. 

This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.

Contacts:

Media Relations
(781) 208-0160
media@invivyd.com

Investor Relations
(781) 208-1747
investors@invivyd.com

FAQ

What did Invivyd (IVVD) announce about inducement option grants on March 1, 2026?

Invivyd granted options for an aggregate of 192,000 shares to four new non-executive hires. According to the company, grants were made under Nasdaq Listing Rule 5635(c)(4) and the Invivyd 2026 Inducement Plan to incentivize new employees.

What is the exercise price and term of the Invivyd (IVVD) inducement options granted March 1, 2026?

The options have a $1.69 per-share exercise price and a 10-year term. According to the company, $1.69 equals the closing price on Feb 27, 2026, the last trading day before the grant.

How do the Invivyd (IVVD) inducement options vest for the newly hired employees?

Each option vests over four years: 25% after the first anniversary, then monthly thereafter. According to the company, vesting is subject to each employee’s continuous service with Invivyd.

Under which plan and Nasdaq rule were Invivyd (IVVD) inducement options granted?

The grants were made under the Invivyd 2026 Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4). According to the company, this rule permits inducement awards for newly hired employees.

How many employees received inducement options from Invivyd (IVVD) and what was the total share amount?

Four newly hired non-executive employees received options totaling 192,000 shares. According to the company, the awards were intended as material inducements for each employee’s entry into employment.